DRUG

dextromethorphan

8 hypotheses across 3 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

dextromethorphan appears in hypotheses across 3 disease domains: ALS, Epilepsy, Multiple sclerosis. Shared mediators that recur across at least two of those domains: NMDA receptor.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for dextromethorphan

ALS 2

Mediator Outcome Score Tier Lit. status Trial
NMDA receptor pain 0.208 Mid reproduces known active
NMDA receptor cell-autonomous excitotoxicity 0.208 Mid novel signal none

Epilepsy 2

Mediator Outcome Score Tier Lit. status Trial
NMDA receptor neuronal death 0.208 Mid reproduces known none
NMDA receptor neurodevelopmental disorders 0.208 Mid partial evidence completed

Multiple sclerosis 4

Mediator Outcome Score Tier Lit. status Trial
NMDA receptor neuronal degeneration 0.208 Mid partial evidence none
NMDA receptor calcium accumulation 0.208 Mid novel signal none
NMDA receptor actin destabilization 0.208 Mid novel signal none
NMDA receptor deterioration of visual acuity 0.208 Mid novel signal none

Clinical trials

200 registered trials for dextromethorphan

Source: ClinicalTrials.gov